Ashutosh D Wechalekar
Overview
Explore the profile of Ashutosh D Wechalekar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
6113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Porcari A, Razvi Y, Cappelli F, Nitsche C, Serenelli M, Longhi S, et al.
JAMA Cardiol
. 2025 Jan;
PMID: 39841451
Importance: Patients with transthyretin (ATTR) cardiac amyloid infiltration are increasingly diagnosed at earlier disease stages with no heart failure (HF) symptoms and a wide range of cardiac amyloid infiltration. Objective:...
2.
Jamroziak K, Zielonka K, Khwaja J, Wechalekar A
Br J Haematol
. 2025 Jan;
206(3):817-831.
PMID: 39748220
Systemic light chain (AL) amyloidosis is a rare clonal plasma cell disorder characterized by the production of amyloidogenic immunoglobulin light chains, which causes the formation and deposition of amyloid fibrils,...
3.
Porcari A, Masi A, Martinez-Naharro A, Razvi Y, Patel R, Ioannou A, et al.
JAMA Cardiol
. 2024 Aug;
9(11):982-989.
PMID: 39167388
Importance: Cardiac amyloid infiltration is the key determinant of survival in systemic light-chain (AL) amyloidosis. Current guidelines recommend early switching therapy in patients with a nonoptimal or suboptimal response regardless...
4.
Bomsztyk J, Ravichandran S, Khwaja J, Cohen O, Rauf M, Foard D, et al.
Br J Haematol
. 2024 Jun;
205(1):138-145.
PMID: 38840512
Bortezomib is regularly used as frontline therapy for systemic AL amyloidosis. We assess the efficacy of second-line daratumumab-bortezomib-dexamethasone (DVD) in AL amyloidosis in bortezomib-exposed patients. A total of 116 patients...
5.
Chiaro G, Stancanelli C, Koay S, Vichayanrat E, Sander L, Ingle G, et al.
Clin Auton Res
. 2024 May;
34(3):341-352.
PMID: 38769233
Background: The cardiomyopathic and neuropathic phenotype of hereditary transthyretin amyloidosis are well recognized. Cardiovascular autonomic dysfunction is less systematically and objectively assessed. Methods: Autonomic and clinical features, quantitative cardiovascular autonomic...
6.
Wechalekar K, Hutt D, Quigley A, Whelan C, Chan P, Hossen L, et al.
Nucl Med Commun
. 2024 Jan;
45(4):253-262.
PMID: 38275011
No abstract available.
7.
Cheng R, Kittleson M, Wechalekar A, Alvarez-Cardona J, Mitchell J, Macedo A, et al.
Heart
. 2024 Jan;
110(12):823-830.
PMID: 38267197
The prevalence of amyloidosis has been increasing, driven by a combination of improved awareness, evolution of diagnostic pathways, and effective treatment options for both transthyretin and light chain amyloidosis. Due...
8.
Bomsztyk J, Ravichandran S, Giles H, Wright N, Berlanga O, Khwaja J, et al.
Blood
. 2024 Jan;
143(13):1259-1268.
PMID: 38194690
Amyloidogenic serum free light chains (sFLCs) drive disease progression in AL amyloidosis. Matrix-assisted laser desorption/ionization time of flight mass spectrometry-based FLC assay (FLC-MS) has greater sensitivity than conventional sFLC assays...
9.
Khwaja J, Bomsztyk J, Atta M, Bygrave C, Forbes A, Durairaj S, et al.
Br J Haematol
. 2024 Jan;
204(5):1811-1815.
PMID: 38171355
Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple-class refractory disease. We report the use of belantamab mafodotin, a BCMA-directed drug-antibody conjugate,...
10.
Razvi Y, Ioannou A, Patel R, Chacko L, Karia N, Riefolo M, et al.
Eur J Heart Fail
. 2023 Nov;
26(2):383-393.
PMID: 37953725
Aims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure. A total of 3-4% of individuals of African descent carry a TTR gene mutation encoding the p.(V142I)...